Bayer's Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies

WAYNE, N.J., Dec. 8, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. today announced that at a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA), the majority of Advisory Committee members voted (15 to 11) that the benefits of drospirenone-containing combination oral contraceptives (COCs) in the prevention of pregnancy outweigh the potential risks.  The Committee members also voted (21 to 5) that the current labels for Bayer's drospirenone-containing combination oral contraceptives do not adequately reflect the risk benefit profile for these products and should be revised to include additional information from available studies. 

Recommendations from the Committees will be considered by the FDA in making its final decision. 

"We thank the Committee members for their efforts and participation in the discussion on the benefit-risk profile for drospirenone-containing combination oral contraceptives," said Pamela A. Cyrus, M.D., Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. 

Bayer has consistently worked with the FDA and other regulatory authorities around the world as new data have become available regarding drospirenone-containing COCs, and has worked with the agencies to make label updates as appropriate.  Bayer will continue to do so.

About Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals, Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-Looking Statement:

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer and the Bayer Cross are registered trademarks of Bayer HealthCare Pharmaceuticals.

SOURCE Bayer HealthCare Pharmaceuticals, Inc.